Rima Kaddurah-Daouk

Rima Kaddurah Daouk

Dr. Kaddurah Daouk is a Professor in Departments of Psychiatry and Medicine at the Duke University Medical Center. A graduate of the American University of Beirut department of biochemistry with subsequent training in molecular biology at Johns Hopkins where she worked with Noble Laureate Hamilton Smith working on restriction endonucleases... during a fellowship at Massachusetts General Hospital and as research staff at the Massachusetts Institute of Technology she developed supporting evidence for a role for creatine kinase and impaired mitochondrial energetics in neurodegenerative diseases including ALS and Parkinson disease.

She has been a seminal force in development of applications for metabolomics in the medical field. She co-founded the Metabolomics Society and served over four years as its founding president helping create presence and voice for an interactive metabolomics community. She cofounded Metabolon, a leading biotechnology company for applications in metabolomics. With significant funding from NIH she established and leads large consortia that includes over 150 scientists from over thirty academic institutions. The “Mood Disorder Precision Medicine Consortium” (MDPMC) funded by NIMH seeks to optimize treatment outcomes in depression. The “Alzheimer’s Disease Metabolomics Consortium” funded by NIA and in partnership with the Alzheimer's Disease Neuroimaging Initiative is one out of six consortia under Accelerated Medicine Partnership for Treatment of Alzheimer Disease (AMPAD) and Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease (M²OVE-AD) initiatives set to respond to President Obama’s challenge to prevent or treat Alzheimer’s disease by 2025 “A Plan to Address Alzheimer Treat or Prevent by 2025”.

Through the “Pharmacometabolomics Research Network” funded by NIGMS she established foundations for a new filed “Pharmacometabolomics” that parallels and informs pharmacogenomics and where metabolic profiles of individuals are used to inform about treatment outcomes.

Over the past decade she has been developing tools to enable precision medicine approaches... she leads the Precision Medicine Task Group within the Metabolomics Society and serves on the board of the newly established Metabolomics Association of North America.